短周期静脉注射免疫球蛋白治疗类脂质渐进性坏死性血管病。 - Suppr

Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins.

作者信息

Pitarch Gerard, Rodríguez-Serna Mercedes, Torrijos Arantxa, Oliver Vicente, Fortea José Miguel

出版信息

Acta Derm Venereol. 2005;85(4):374-5. doi: 10.1080/00015550510027865.

DOI:10.1080/00015550510027865

PMID:16191872

Abstract

摘要

相似文献

Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins.

Acta Derm Venereol. 2005;85(4):374-5. doi: 10.1080/00015550510027865.

Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.

J Am Acad Dermatol. 2014 Oct;71(4):738-44. doi: 10.1016/j.jaad.2014.05.039. Epub 2014 Jul 9.

Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity.

Arch Dermatol. 2011 Oct;147(10):1224-5. doi: 10.1001/archdermatol.2011.274.

Livedoid vasculopathy: what it is and how the patient should be evaluated and treated.

Arch Dermatol. 2006 Nov;142(11):1481-2. doi: 10.1001/archderm.142.11.1481.

The cutting edge: Thalidomide for type 1 cryoglobulinemic vasculopathy.

Arch Dermatol. 2006 Aug;142(8):972-4. doi: 10.1001/archderm.142.8.972.

[Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies].

Ann Med Interne (Paris). 2000 Sep;151(5):408-10.

A case of livedoid vasculopathy in a 22-year-old man.

J Drugs Dermatol. 2004 Nov-Dec;3(6):678-9.

Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia.

Arch Dermatol. 2006 Jan;142(1):75-8. doi: 10.1001/archderm.142.1.75.

Recurrent cutaneous eosinophilic vasculitis presenting as annular urticarial plaques.

Acta Derm Venereol. 2005;85(4):380-1. doi: 10.1080/00015550510030113.

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.

Arch Dermatol. 2006 Nov;142(11):1466-9. doi: 10.1001/archderm.142.11.1466.

引用本文的文献

Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.

Cureus. 2022 Aug 27;14(8):e28485. doi: 10.7759/cureus.28485. eCollection 2022 Aug.

Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.

Ther Adv Chronic Dis. 2022 May 22;13:20406223221097331. doi: 10.1177/20406223221097331. eCollection 2022.

Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Int J Womens Dermatol. 2021 Sep 2;7(5Part A):588-599. doi: 10.1016/j.ijwd.2021.08.013. eCollection 2021 Dec.

Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.

Clin Case Rep. 2018 Sep 12;6(11):2045-2047. doi: 10.1002/ccr3.1803. eCollection 2018 Nov.

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.

JMIR Res Protoc. 2014 Dec 10;3(4):e73. doi: 10.2196/resprot.3640.

Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

J Thromb Thrombolysis. 2008 Aug;26(1):31-4. doi: 10.1007/s11239-008-0214-1. Epub 2008 Mar 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献